The leading European partnering event for early-stage deals and investment rounds in the Life Sciences field

HYBRID FORMAT

November 29th & 30th, 2022
IN-PERSON | STRASBOURG

December 7th & 8th, 2022
☐ 100% ONLINE
Welcome!

We are absolutely delighted to welcome you back to Strasbourg for the 11th edition of BioFIT, the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field. It is a real pleasure to be back in-person after two years of 100% digital events.

Since its launch in 2010, BioFIT has been committed to providing its 1000 participants with interactions and meeting times to foster innovation partnerships and the development of innovative health solutions. This is why it was important for us to offer you a hybrid solution for this 2022 edition, in order to maintain the quality and diversity of the event’s exchanges on an international scale.

This year again, BioFIT offers numerous activities such as one-on-one meetings with pre-identified actors, four conferences tracks in the Life Sciences and Animal Health fields, a pitch competition, a matchmaking activity between projects and CEOs, and an exhibition area.

We wish you a productive and enjoyable event, with a variety of meetings and partnership opportunities!

The BioFIT organisers

Etienne Vervaecke  
General Manager  
Eurasanté Clubster NHL

Emile Royere  
General Manager  
Eurobiomed

Caroline Dreyer  
General Manager  
BioValley France

Test HEK293 Media in Your Suspension Culture

Free Media Sample Kit for Gene Therapy Applications and Viral Vector Vaccines

Our 4 high performing HEK media are designed to best fit with the high variability of HEK293 cell lines, the variety of transfection reagents and viral vector processes.

Test, identify, and select the best matching HEK media for your individual requirements with our free HEK293 media sample kit.

Ask a Sartorius team member to sign up for yours today.

Scan to request your free HEK293 media sample kit
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started.

BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and to source early-stage innovation stemming from public research institutions, academic spin-offs and emerging biotech companies. Together with big pharma, biotech and diagnostic companies, BioFIT operates as a platform to build partnerships for all actors from academia and industry.

BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.
ORGANISERS

www.eurasante.com
Eurasanté is a technology transfer tool, an incubator, an accelerator and a cluster manager in the Health field in Northern France. Eurasanté assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The region includes over 1,000 healthcare companies with 32,000 employees in this sector. Eurasanté also promotes and develops the Eurasanté bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories within an European-wide scientific and medical site. Eurasanté also organises four international healthcare-related partnering events that aim to increase and improve interaction between academia and industry: BioFIT (Life Sciences), MedFIT (MedTech, Diagnostic, Digital Health), NutrEvent (Food, Feed, Nutrition, Health) and AgeingFit (Healthy Ageing).

www.clubster-nsl.com
Clubster NHL is a competitiveness cluster and a network gathering 350 members committed to innovation in health and nutrition. Clubster NHL aims to connect academia, industry and health professionals, and to foster innovation for better health and sustainable food. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.

www.eurobiomed.com
Founded in 2009 by regional stakeholders, Eurobiomed is the Life Science cluster from Southern France. We gather more than 390 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities. We lead territorial initiatives and help our members businesses and research organisations to innovate, finance, develop and achieve their scientific and business objectives, to ultimately improve the treatment and the lives of patients.

Invest for Success
www.eurasante.com
Eurasanté is a technology transfer tool, an incubator, an accelerator and a cluster manager in the Health field in Northern France. Eurasanté assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The region includes over 1,000 healthcare companies with 32,000 employees in this sector. Eurasanté also promotes and develops the Eurasanté bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories within an European-wide scientific and medical site. Eurasanté also organises four international healthcare-related partnering events that aim to increase and improve interaction between academia and industry: BioFIT (Life Sciences), MedFIT (MedTech, Diagnostic, Digital Health), NutrEvent (Food, Feed, Nutrition, Health) and AgeingFit (Healthy Ageing).

www.clubster-nsl.com
Clubster NHL is a competitiveness cluster and a network gathering 350 members committed to innovation in health and nutrition. Clubster NHL aims to connect academia, industry and health professionals, and to foster innovation for better health and sustainable food. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.

www.eurobiomed.com
Founded in 2009 by regional stakeholders, Eurobiomed is the Life Science cluster from Southern France. We gather more than 390 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities. We lead territorial initiatives and help our members businesses and research organisations to innovate, finance, develop and achieve their scientific and business objectives, to ultimately improve the treatment and the lives of patients.

Invest for Success
www.eurasante.com
Eurasanté is a technology transfer tool, an incubator, an accelerator and a cluster manager in the Health field in Northern France. Eurasanté assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The region includes over 1,000 healthcare companies with 32,000 employees in this sector. Eurasanté also promotes and develops the Eurasanté bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories within an European-wide scientific and medical site. Eurasanté also organises four international healthcare-related partnering events that aim to increase and improve interaction between academia and industry: BioFIT (Life Sciences), MedFIT (MedTech, Diagnostic, Digital Health), NutrEvent (Food, Feed, Nutrition, Health) and AgeingFit (Healthy Ageing).

www.clubster-nsl.com
Clubster NHL is a competitiveness cluster and a network gathering 350 members committed to innovation in health and nutrition. Clubster NHL aims to connect academia, industry and health professionals, and to foster innovation for better health and sustainable food. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.

www.eurobiomed.com
Founded in 2009 by regional stakeholders, Eurobiomed is the Life Science cluster from Southern France. We gather more than 390 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities. We lead territorial initiatives and help our members businesses and research organisations to innovate, finance, develop and achieve their scientific and business objectives, to ultimately improve the treatment and the lives of patients.

Invest for Success
www.eurasante.com
Eurasanté is a technology transfer tool, an incubator, an accelerator and a cluster manager in the Health field in Northern France. Eurasanté assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The region includes over 1,000 healthcare companies with 32,000 employees in this sector. Eurasanté also promotes and develops the Eurasanté bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories within an European-wide scientific and medical site. Eurasanté also organises four international healthcare-related partnering events that aim to increase and improve interaction between academia and industry: BioFIT (Life Sciences), MedFIT (MedTech, Diagnostic, Digital Health), NutrEvent (Food, Feed, Nutrition, Health) and AgeingFit (Healthy Ageing).

www.clubster-nsl.com
Clubster NHL is a competitiveness cluster and a network gathering 350 members committed to innovation in health and nutrition. Clubster NHL aims to connect academia, industry and health professionals, and to foster innovation for better health and sustainable food. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.

www.eurobiomed.com
Founded in 2009 by regional stakeholders, Eurobiomed is the Life Science cluster from Southern France. We gather more than 390 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities. We lead territorial initiatives and help our members businesses and research organisations to innovate, finance, develop and achieve their scientific and business objectives, to ultimately improve the treatment and the lives of patients.

Located in the heart of Europe, the Grand Est region is a dynamic region that is involved in health issues and benefits from a state-of-the-art ecosystem.

The Grand Est region concentrates all the players in the health ecosystem: pharmaceutical industries, including biomanufacturing, manufacturers of medical devices and producers of diagnostic tools, etc. In addition, the local concentration of players from other innovative sectors such as materials and digital creates a privileged cradle for generating interactions and collaborations.

The European metropolis of Strasbourg and the Grand Est region are a high place of the Life Sciences, at the cross-border region characterised by a strong culture of Franco-German-Swiss cooperation. The BioValley region concentrates a unique density of actors of excellence in Life Sciences and Health with no less than 5 Nobel Prize winners, global-renowned research institutes and more than 420 companies, ranging from innovative start-ups to pharmaceutical giants.
FINDMED is a consortium of 18 French leading research institutions involved in healthcare at large, that have received the “Carnot” label for their ability to conduct R&D partnerships with companies.

FINDMED’s mission is to help French companies, in particular start-up and SMEs, to access the expertise and the technological platforms of its members.

FINDMED is therefore companies’ R&D partner for their innovation projects, whether they be biotech and/or medtech.

Working with the life-science community to be first4patients

Inspired by patients, driven by science and powered by our growing global community of partners, we’re working hard to discover and develop the next generation of transformative medicines that will change patients’ lives.
We deliver the industry’s most comprehensive portfolio of high-quality products, services and testing for biopharmaceutical manufacturing.

We are proud to provide drug manufacturers with process development expertise and technologies, such as continuous bioprocessing.

We collaborate with the world’s leading drug developers to help bring drug therapies to patients. We bring our pharmaceutical and biotechnology expertise and products to improve every step of the manufacturing process, while providing startups with holistic support to build and scale up theirs.

Merck’s presentation: A holistic approach to speed up upstream process development for the production of biopharmaceuticals

Speakers:
- Alexandre Laly, Customer Application Consultant – Emerging Biotech
- Sarah Timp, Technical Application Consultant for Upstream Processing

Wednesday, November 30th | 10.30 - 11.00 am | Innov'Area

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world’s poorest countries.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

Sanofi’s presentation: Why partner with Sanofi?
Speaker: Murielle Gitton, Head R&D Transactions
Tuesday, November 29th | 3.15 - 3.30 pm | Innov'Area
An independent group committed to therapeutic progress to serve patient needs

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

Zoetis’ presentation: **Innovation and One Health: How can monoclonal antibodies offer new perspectives in veterinary medicines?**

Speakers:
- Olivier Martinon, Vice President External Innovation & Research Alliances and LIBRELA Project Leader
- Hervé de Cidrac, Senior Vice President General Manager Cluster France

Tuesday, November 29th | 2.30 - 3.00 pm | Madrid 1room

Sartorius’ presentation: **Cell culture media and testing solution capabilities**

Speaker: Luka Kadovic, Field Application Specialist CMTS

Wednesday, November 30th | 11.45 am - 12.00 pm | Madrid 1room

Sartorius Stedim Biotech is a leading partner of the biopharma industry. Our solutions are supporting our customers to produce drugs safely, timely and economically. The key product categories of our company are cell cultivation, fermentation, filtration, purification, and fluid management.

As the world’s leading animal health company, we are driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, we continue to stand by those raising and caring for animals worldwide - from livestock farmers to veterinarians and pet owners. A Fortune 500 company, we generated revenue of $7.8 billion in 2021 with ~12,100 employees. For more, visit www.zoetis.com.

www.zoetis.com
www.sartorius.com
Boehringer Ingelheim International

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Boehringer Ingelheim Animal Health

As a global leader in the animal health industry our more than 10,000 employees serve more than 150 markets worldwide. We are one of the largest providers of vaccines, parasiticides and therapeutics. With a strong presence in the companion animal and livestock segments, we support veterinarians, farmers as well as pet and horse owners. As part of family-owned Boehringer Ingelheim, we are rooted in our family values and take a long-term perspective.

FINDMED is a consortium of 18 French leading research institutions involved in healthcare at large and that have got the “Carnot” label for their ability to conduct R&D partnerships with companies. FINDMED’s mission is to help French companies, in particular start-ups and SMEs, to access the expertise and the technological platforms of its members. FINDMED is therefore companies’ R&D partner for their innovation projects, whether they be biotech and/or MedTech.

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterised by high unmet medical needs. GENFIT is a pioneer in the research and development of therapeutic and diagnostic solutions in liver diseases, with a rich history and strong scientific heritage spanning more than two decades. Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialisation stages, today GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions.

Servier is a global independent pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7B in 2021, Servier employs 21,800 people worldwide. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. Servier growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neurosciences and immuno-inflammatory diseases.

More information: www.servier.com
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China.

Acrobiosystems.com

Capital Grand Est is an asset management company based in Strasbourg – France. The company manages over 80M. Capital Grand Est is mainly focused on investing in growing SMEs and promising young start-ups located in the eastern part of France.

Capitalgrandest.eu

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide… and many of these advances were the result of partnerships. In 2016, more than 60% of our human health sales were attributable to alliance partnerships and patents and we continue to work with our partners in some of the most challenging areas of biomedical research. With more than 100 business development transactions since 2015, our team has experience working on collaborations from discovery to clinical-stage programs regardless of therapeutic area or modality. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life.

Msds.com

Ipsen is a public global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of 2.6bn in FY 2021 Ipsen sells medicines in over 100 countries. Ipsen has 5,000 employees worldwide and innovative research located in leading biotechnological and life science hubs in France, UK, US and China. For more information, visit ipsen.com and get in touch with our partnering team!

Ipsen.com

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us.

Pfizer.com

Pfizer CentreOne® is a global CDMO within Pfizer and a leading supplier of specialty APIs. Our global manufacturing network includes more than 35 sites across six continents. Backed by Pfizer resources, we deliver technical expertise, global regulatory support and long-term supply. Working together with our customers, we combine our knowledge with open dialogue to solve challenges. For more information, visit www.pfizercentreone.com.
Roche is the world’s largest biotech company and #1 investor into R&D, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the CNS. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare. Our Pharma Partnering team provides comprehensive BD and alliance management support for Roche and Genentech’s R&D units and the broader pharmaceutical division. Alongside the broad internal pipeline, external innovation has always been a critical component of our R&D strategy.

AdBio partners (previously Advent France Biotechnology) is an AMF-regulated (the French financial market authority) company that invests in a range of sectors within life sciences - specifically in therapeutics-oriented projects. AdBio partners’ unique strategy combines early-stage investments in promising enterprises and strong entrepreneurial support to strengthen the company’s growth. Created in 2016, AdBio partners has made 17 European investments in France, Belgium, Spain and Ireland. AdBio partners has developed strong relationships within the European innovation ecosystem; as a result, it has attracted international VC syndicates to its portfolio companies. The operational team is managed by Alain Huriez and Matthieu Coutet. It has appointed a number of investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific and medical expertise.

X’PROCHEM is a biotech company specialised in chemical synthesis of proteins for therapeutic and diagnostic use. We are able to design and produce complex and highly customised proteins thanks to our robotic technology. We can help you to produce proteins that are:
- Difficult to produce or to purify
- Need unnatural amino acids
- More efficient and reliable
- Proteins composed of up to 400 amino acids
- Contain a precise modification in the protein sequence
Our proteins are guaranteed:
- High purity
- No endotoxins or biological contaminants
- No isoforms

We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. We employ more than 50,000 people in 80 offices around the world, and market our products in 170 countries.
### Tuesday, November 29th

<table>
<thead>
<tr>
<th>Time</th>
<th>MADRID 1 room</th>
<th>MADRID 2 room</th>
<th>ROOMS</th>
<th>Pitch Sessions</th>
<th>Partnering</th>
<th>Exhibition area</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30 am</td>
<td>Welcome coffee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.00 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.30 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30 am</td>
<td>Networking break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00 am</td>
<td>PLENARY SESSION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Partnering off the beaten path: How are early-stage biotech collaboration dynamics changing?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30 pm</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.30 pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.00 pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.30 pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.00 pm</td>
<td>Networking break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.00 pm</td>
<td>Best practices in Alliance Management: The keys to building successful partnerships</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.30 pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Wednesday, November 30th

<table>
<thead>
<tr>
<th>Time</th>
<th>MADRID 1 room</th>
<th>MADRID 2 room</th>
<th>ROOMS</th>
<th>Pitch Sessions</th>
<th>Partnering</th>
<th>Exhibition area</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30 am</td>
<td>Welcome coffee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.00 am</td>
<td>Biotech start-ups: Communicating the investment value of an idea as well as the science</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.30 am</td>
<td>Networking break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00 am</td>
<td>Rules of attraction: What makes pharma engage in collaboration or licensing with academia?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00 am</td>
<td>Recent developments in the early-stage biotechnology investment landscape</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.45 pm</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.00 pm</td>
<td>What do pharma companies look for in a licensing agreement?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.30 pm</td>
<td>Networking break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.30 pm</td>
<td>How is digital health shaping new forms of early-stage collaborations in biopharma?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.30 pm</td>
<td>Award Ceremony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Times are CET**
CONNECTING TO THE WIFI

1. Choose « BioFIT_FreeWifi » network
   Password « EnjoyBioFIT2022 »

2. A page opens: fill the form and check the box

3. Click on « Connexion »
ONE-ON-ONE MEETINGS

The BioFIT partnering activity is the best way to identify and connect with potential businesss, research and financial partners.

4 DAYS TO MEET YOUR FUTURE PROJECT PARTNERS, OBTAIN FUNDING AND ACCELERATE INNOVATION

How to organise your meetings onsite?

- Print out your meeting schedule, which includes meeting times and locations, at the Partnering Desk.
- Attend your one-on-one meetings at the scheduled time and indicated place.
- Continue to monitor your partnering account on biofit2022.vimeet.events throughout the event at the partnering desk.

BioFIT’s partnering platform is powered by:

You didn’t get the chance to schedule all of your meetings?
BioFIT continues online on December 7th and 8th.

Who will you meet?

25% TTOs, Research institutions, Incubators, Academics
20% Pharma & Diagnostic companies
20% Biotech companies
15% R&D services - Preclinical CROs and CDMOs
10% Investors (pre-seed, seed and Series A)
5% Consulting companies, law firms
5% Associations, clusters, media

Using the power of leading-edge science to save and improve lives around the world

For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for some of the world’s most challenging diseases.

At MSD, we rise to the challenge in pursuit of better health outcomes.

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. HQ-NON-00991 7/22
**PROJECT - CEO MATCHMAKING**

*Are you a bioentrepreneur seeking a project? Or do you have projects needing a CEO?*

As talented CEOs are frequently sought-after by many players in the biotech industry, the Project - CEO matchmaking activity aims to connect representatives of emerging start-ups, technology transfer offices, incubators and investing networks with CEOs and aspiring CEOs.

**Find the perfect match**

- Any incubator, technology transfer entity or scientific founder looking for an entrepreneur to lead their start-up project is welcome at BioFIT and in particular at the matchmaking activity between projects and CEOs. You will be visible on the partnering platform, to be contacted by potential CEOs.

- If you are a bioentrepreneur looking for a project to get involved in, projects looking for a CEO will be visible on the platform and easily identifiable.

**Get inspired**

Having the right team is essential for the development of a biotech project or start-up. The Project - CEO matchmaking activity also offers a conference session to get inspired and explore the best ways to find the right talent for a successful project.

**How to source the right talents for an early-stage company?**

How to identify and retain talents with the necessary soft skills and technical expertise to drive growth and innovation? How to find the right co-founders? Which networks to activate? Hear from startup management savvy experts and receive feedback and best practices.

**Tuesday, November 29th | 2.00 - 3.00 pm**

*Rome room*

**INVESTOR LUNCH**

BioFIT has the pleasure to organise an **Investor Lunch** on **November 30th** at 12.45 pm.

This dedicated lunch will offer the opportunity to investors to **discuss early-stage investment trends** and exchange on the **2022 highlights**. Most importantly, this networking time will be the perfect moment to solidify co-investment networks.

*Investors can sign-up online prior to the event and on-site at the partnering desk before November 30th.*

**Moderator**

Jim Cornall
Editor in Chief
Labiotech.eu

Dorothée Gueras
Tricart
Head of Biotech division
Eurasanté

Gregoire Prevost
Founder & CEO
Ciprevo

Albin Jeanne
President & CSO
Apmonia Therapeutics

Melya Hughes
Crameri
Partner
Ventac Partners
The BioFIT pitch sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects and licensing opportunities in order to foster partnerships and business development in the Life Sciences and Animal Health fields.

The most innovative start-up, most promising technology and most innovative animal health project will be announced during the Award Ceremony on November 30th, from 4.30 pm, within the Innov’Area.

On-demand videos of the 2022 pitchers will be available from December 7th and for 30 days afterwards!

JURY MEMBERS

- Alexandre Breda, Biotech Start-up Manager, Eurasanté
- Gary Breit, CEO, Breit Ideas LLP
- Vincent Bricard, Venture Partner, EQT Life Sciences
- Zuzanna Brzosko, Senior Director, Corporate Strategy & External Innovation, Eli Lilly and Company
- Ivan Burkov, Principal, Inkef
- Florence Dal Degan, Senior Director, External Innovation, Rare Diseases and Neurosciences, Ipsen
- Isabelle Dupin-Roger, Director, R&D External Innovation | Neuroscience and Immuno-inflammation, Servier
- Dorothée Gueras Tricart, Head of Biotech division, Eurasanté
- Monique Guis, External Innovation Immunology Director, Sanofi
- Frank Hensel, Principal, High-Tech Gründerfonds
- Dmitrii Hristodorov, Partner, Forbion
- Lydia Kalafateli, Venture Developer, NLC Health
- Alexandre Laly, Customer Application Consultant - Emerging Biotech, Merck
- Esther Lange, Industry Liaison Manager, Ascenion
- Marie-Ange N’Zoutani, Head of Acceleration office Sanofi Partnering, Sanofi
- Richard Reschen, Associate Director, BD&L Europe, MSD
- Olaf Ritzeler, BD&L, Director, Rare Diseases External Innovation / GLOBAL, Sanofi
- Corinne Szilagyi, Senior Partner, Biotech Development Conseils & Member of the Business Development Committee, France Biotech
- Kristin Thompson, VP, Chief Business Officer, eureKARE
- Joachim Vogt, Director, Search and Evaluation, Western Europe, AbbVie
- Ulrich Zügel, Senior Director Emerging Science & Innovation Lead - Inflammation & Immunology Europe, Pfizer
- Jean-Christophe Audonnet
- Jean-Louis Hunault, President, SIMV
- Theo Kanellos, Director Business Development and commercial Alliances, Zoetis
- Jean-Pascal Marc, Corporate Product Innovation Director, Virbac
- Edouard Timsit, Senior Innovation Scientist, Ceva Santé Animale

START-UP SLAMS

The Start-up Slams are a great opportunity for young companies (and particularly for start-ups seeking to raise a seed or a Series A financing round) to showcase their project in front of potential partners and investors.

Tuesday, November 29th | 9.30 – 10.30 am

DIAGNOSTIC

LIFESPIN GMBH Stand A2
Personalised health | Precision medicine | Digital metabolic signature

PARAMEDIR Stand IA1 on November 29th
Continuous monitoring | Intensive care | Kidney disease (AKI)

PROSTPERIA Stand IA2 on November 29th
Personalised medicine | Cancer screening | Artificial intelligence

SIBIUS Stand IA3 on November 29th
Cognitive disorders | Artificial intelligence | Detection

WAINVAM-E Stand B3
Detection | Sensitivity | Nanodiamonds

Tuesday, November 29th | 3.30 – 4.30 pm

INFLAMMATION

MEXBRAIN Medical device | Metals | Dialysis

SPARTHA MEDICAL Stand B6/6
Antimicrobial, anti-inflammatory and antiviral coatings | Biopolymers | Supramolecular assembly

VAPTOL (APTEEUS) Anti-inflammatory drug | Pneumonia | Inhalation
START-UP SLAMS

**DRUG DEVELOPMENT**

**MARACELLS** (Stand IA4 on November 29th)
Cell culturing | Glucose | Online monitoring

**VENTIO** (Stand IA5 on November 29th)
Biomedical imaging | Quantitative susceptibility mapping | Brain biomarker

**LAB COMPLIANCE**

**ARXUM** (Stand A9)
Blockchain | Innovation | Compliance

**CELL & GENE THERAPY**

**EG 427** (Stand IA2 on November 30th)
Peripheral nervous system | Redosable | Large payload

**CORE BIOGENESIS**
Bioproduction | Proteins | Cell therapy

**DE NOVO CELL LTD**
Stemcell therapy | Personalised medicine | Biotechnology

**THERAPEUTICS**

**APMONIA THERAPEUTICS**
Tumor microenvironment | Peptide | Immunotherapy

**KARLA THERAPEUTICS** (Stand IA3 on November 30th)
Precision medicine | Mental health | Immunology

**ODIMMA THERAPEUTICS** (Stand IA4 on November 30th)
Personalised immunotherapy platform | DNA based technology | Artificial Intelligence

START-UP SLAMS

**ONCOLOGY**

**BIPER THERAPEUTICS** (Stand B6/5)
Cancer | First-In-Class | ER stress

**CASINVENT PHARMA** (Stand IA5 on November 30th)
Oncology | Leukemia | Casein kinase 1

**REAL RESEARCH** (Stand IA11 on November 30th)
3D cell culture | Research models | Cancer

**THERATRAME** (Stand IA7 on November 30th)
Oncology | tRNA | Drug discovery

**DRUG DELIVERY**

**ALBUPAD** (Stand IA8 on November 30th)
Protein-based materials | Drug delivery | Green technology

**DYNABIND GMBH**
Drug discovery | Small molecules | DNA-Encoded Library

**ELASTRIN THERAPEUTICS INC** (Stand IA9 on November 30th)
Cardiovascular | Regenerative medicine | Elastin repair
The Collaborative and Licensing Opportunity Presentations enable TTOs, universities, research institutes and companies to showcase their early-stage technologies in front of potential partners, in order to entail a collaborative project and/or a licensing deal.

**Tuesday, November 29th | 2.00 – 3.00 pm**

**LAB & RESEARCH TOOL**

**ACTOME** | Stand A3
Proteomics | Protein-protein interactions (PPI) | Post translational modifications (PTM)

**ELEMENTA LABS B.V.** | Stand IA11 on November 29th
AI | Voice-technology | Pharma & Life Sciences

**MAX PLANCK INSTITUTE FOR TERRESTRIAL MICROBIOLOGY** | Stand IA12 on November 29th
Lifespan | High-throughput | Yeast

**CARDIOVASCULAR**

**IMPERIAL COLLEGE LONDON – MAP4K4 INHIBITORS** | Stand IA13 on November 29th
Cardiac injury | Small molecule inhibitor | MAP4K4

**MONITORING**

**INSPEK** | Stand IA10 on November 29th
Process analytical technologies | Real-time, in-situ monitoring | Single-use technologies

**Wednesday, November 30th | 9.00 – 10.00 am**

**METABOLIC**

**UNIVERSITY OF PISA – METABOLISM** | Stand IA12 on November 30th
GLP-1 secretion | Diabetes | Obesity

**CNS**

**SATT CONECTUS – DELIS-ALZ** | Stand IA1 on November 30th
Sigma1 | Neurodegeneration | Cognitive impairments

**DIAGNOSTIC**

**IMPERIAL COLLEGE LONDON – NANOSCALE TWEEZERS** | Stand IA13 on November 30th
Single-cell manipulation | Biomolecule extraction | Non-destructive trapping

**KU LEUVEN** | Stand IA10 on November 30th
Non-invasive | Functional biomarker | Immuno-oncology

**BIOPRESERVATION**

**IFREMER** | Stand IA6 on November 30th
Biopreservation | Seafood | Beneficial bacteria
ANIMAL HEALTH PRESENTATIONS

The Animal Health Presentations are sponsored by:

SIMV
Boehringer Ingelheim
zoetis

and supported by:

The Animal Health Presentations allow young companies, TTOs, universities, research institutes and companies to showcase their innovative project in front of potential partners and investors in the Animal Health sector.

Tuesday, November 29th | 5.00 – 6.15 pm

ANIMAL HEALTH

IFREMER (I) Stand IA6 on November 29th
Oyster | Herpesvirus | Antiviral stimulation

DEEPTOPE (I) Stand A1
Antibody & protein | Canization & Felinisation | Optimisation

ANIMOSCOPE (I) Stand IA7 on November 29th
Telehealth | Symptom checker | Artificial Intelligence

WEYTS EQUINE VETTING-ALSVID (I) Stand IA8 on November 29th
Laminitis | Horses | Circulation

UNIVERSITY OF LJUBLJANA FACULTY OF PHARMACY (I)
Stand IA9 on November 29th
Canine cognitive dysfunction | Butyrylcholinesterase inhibitor | New drug

Together with our global family of innovation partners, we’re working hard to accelerate the discovery and development of the next generation of breakthroughs in animal health.

CardioMetabolic Diseases | Central Nervous System Diseases | Immunology & Inflammation
Infectious Diseases | Oncology | Oral Health | Pain & Osteoarthritis | Parasitology
Technologies | Digital Science
Steered by a prestigious committee, the BioFIT 2022 conference programme is tailored to match the interests of every actor of the sector. Rooted in four custom-made tracks, the conference sessions bring together international experts to discuss the current stakes of the early-stage innovation in the life sciences sector and focus on:

**CONFERENCE PROGRAMME**

**TRACK 1**

**Best practices in R&D collaborations**
Fostering academia-industry partnerships is key to driving innovation in Life Sciences. Which sectors are prone to fuel collaborations? What are the elements to for gather to merge the scientific, academic, advocacy and industry spheres? How are the advances in specific fields influencing academia-pharma partnerships?

**TRACK 2**

**Nurturing and licensing early-stage assets**
Early-stage assets evolve in an ecosystem where TTOs, scientists and entrepreneurs are closely connected. Understanding the mechanisms and difficulties in nurturing and licensing assets is key to properly influencing the valuation of these assets at an early stage. How can we transform science into business more frequently and efficiently?

**TRACK 3**

**From pre-seed to Series A: Accessing early-stage investment**
This track aims to understand the mechanisms enforcing investors’ presence in early stages of development. Are we witnessing surges of investment in specific therapeutic areas? Who are the new players involved in investing in the biotech sector and what are their pre-requisites?

**TRACK 4**

**Animal Health Highlights**
This track features the latest innovation challenges in animal health R&D and intends to provide a clear understanding of the bridges that can be built between human and animal health. International experts from veterinary research and industry will discuss the latest initiatives to improve and accelerate the development of new diagnostics, vaccines and pharmaceuticals for animal diseases and beyond.

The recording of BioFIT conferences will be available from December 7th and for 30 days afterwards!

---

**Plenary Session**

**Partnering off the beaten path: How are early-stage biotech collaboration dynamics changing?**
As the biopharma industry and individual biotech companies themselves mature, partnering options are also expanding. At the early stages of the drug development life cycle, companies now have options outside of the historical biotech-pharma pair-up.

What other partnership options do biotech companies use today, from translation of academic research to industry and co-development? How do biotech companies identify the right ecosystem and partners? What are the partnering and transaction strategies of small companies in a competitive environment? Are some therapeutic areas more likely to lead to inter-biotech collaborations?
Best practices in R&D collaborations

Tuesday, November 29th | 5.00 – 6.15 pm

Best practices in Alliance Management: The keys to building successful partnerships

The rise of Alliance Management is linked to an increasing number and forms of biopharma R&D collaborations. How do these strategic alliances work and how do they respond to the early-stage strategies of pharma companies? What is the role of an alliance manager and how do they add value to biopharma organisations? What are the concrete impacts of Alliance Management on collaborations?

Rules of attraction: What makes pharma engage in collaboration or licensing with academia?

The industry-academia pair-up has been running for some time in the Life Sciences sector. Yet, the nature of their collaborations has diversified, intensified, and become more complex over the years, leading to more strategic and long-term collaborations and agreements. These changes bring to re-question what the key drivers are for pharma when engaging with academia today. Which business segments or therapeutic areas are favoured? How do pharma companies balance between collaboration, co-development, and straight licensing?

How is digital health shaping new forms of early-stage collaborations in biopharma?

The new pathways created by digital advances in the Life Sciences sector offer R&D actors the opportunity to improve processes, efficiency, and results, all to strengthen the development of their innovations. These advances are now influencing the structure of entire organisations, creating new roles, requiring new skills, and calling for collaboration with new players. How is the digitalisation of the sector driving the appetite of industrials and entailing new collaborations? How is the change of interlocutors in organisations characterised in the context of collaborations between academic researchers, clinicians, and industry?
Nurturing and licensing early-stage assets

Tuesday, November 29th | 9.00 – 10.30 am

Overview of the different models to nurture and de-risk innovative assets

The main challenge for an early-stage asset is to bridge the gap between initial research results and being an exploitable asset. Yet there are a variety of maturation models and initiatives, some of which combine public funding, technology transfer offices, the pharmaceutical industry and venture capital. What are the current models for financing technology maturation? What are the different returns on investment of pre-venture capital tools? Which models currently work and which ones do not?

Tuesday, November 29th | 3.15 – 4.30 pm

The race is on: Will mRNA technology stay attractive for early-stage licensing deals?

The widespread effectiveness of mRNA-based vaccines has attracted considerable attention to the prospect of mRNA technology serving as a platform that can be used to develop an array of preventative and therapeutic medicines, including vaccines for infectious diseases and cancer treatments. While the extent to which mRNA platforms can be used to develop other drugs remains to be seen, what are the prospects and interest in terms of applicability? How is the current IP landscape around this technology? How are biopharma companies building their mRNA capabilities and in which key areas? Is licensing the favoured way to unlock the full potential of mRNA technologies?
From pre-seed to Series A: Accessing early-stage investment

Tuesday, November 29th | 2.00 – 3.00 pm

Getting off to a good start: How to determine the optimal amount to raise to achieve your company's milestones and minimise dilution?

Some dilution is certain when raising venture capital and the situation can quickly become very complex when it comes to evaluating different types of capital, assessing future valuation and share pools. These elements impact the level of dilution entrepreneurs, and their investors may experience over time, so it is crucial to understand the impact of dilution and the alternatives for achieving ownership goals. What are the ways to achieve maximum valuation for a start-up? What strategies can founders apply to best balance the impact of dilution on their ownership and that of their investors through the various stages of their development?

Biotech start-ups: Communicating the investment value of an idea as well as the science

Wednesday, November 30th | 9.00 – 10.00 am

Funding for cutting-edge scientific discoveries is essential to enable the application of science at the pre-commercial stage. While the scientific breakthrough may be obvious, it is not always sufficient in itself, and identifying the commercial opportunities is essential to convince investors. How is the commercial value of a scientific discovery identified and what to do once it has been defined? How to effectively communicate the potential value of the science - which may not be realised for a long time - to attract talent and raise funds? How do you build trust with potential investors?

Recent developments in the early-stage biotechnology investment landscape

Wednesday, November 30th | 12.00 – 12.45 pm

What has been the landscape for venture capital investment in early-stage biotech in 2022 and what to expect in the coming years? Who are the current investors in Seed and Series A biotech: pure players, newcomers? Which funds are the most developed in venture capital? What can we observe in terms of investment geography? Are there significant trends in terms of size of funds and capacity of investment? What are the preferred tools and networks for investment?
Animal Health Highlights

Tuesday, November 29th | 2.30 – 3.00 pm

Innovation and One Health: How can monoclonal antibodies offer new perspectives in veterinary medicines?

Sponsored by: Zoetis

Olivier Martinon
Vice President External Innovation & Research Alliances and LIBRELA Project Leader
Zoetis

Hervé de Cidrac
Senior Vice President General Manager Cluster France
Zoetis

Tuesday, November 29th | 3.15 – 4.30 pm

Funding innovation and start-ups development in animal health

This panel discussion intends to explore the funding sources currently available for early-stage animal health innovations.

What is the role and availability of public funding in animal health innovation?
How prevalent is grant financing and what are its principal orientations? How important are the welfare and public health dimensions in this funding?
How attractive are animal health start-ups to venture capital and who are the investors? Is the European early-stage capital market for animal health rich enough in players and capital?

Moderator
Pascal Breton
Innovation Referent in Human and Animal Health
One Health Pharma

Oliver Boucher
Senior Director Business Development
Zoetis

Eve Hanks
CEO
miRNA Diagnostics

Jarne Elleholm
CEO
Stonehaven Incubate AG

Matthieu Dubruque
Managing Director
Verbillex

Discover an altogether different kind of CDMO

At Pfizer CentreOne, our team is dedicated to making your drug development journey a success with science at its best. A surprisingly refreshing approach, built on a solid foundation for success, our open and collective approach to drug development means we’ll always be transparent with you as we continually strive to deliver on what we promise.

How we can help you
For over 40 years, we’ve walked in your shoes and understand many of the drug development challenges you face. Our open dialogue, compelling science, culture of confidentiality and dedication to long term success have made us the trusted CDMO partner of choice for our customers around the world, and we hope to be yours too.

Discover your trusted CDMO partner of choice
Visit us at www.pfizercentreone.com

We value your ideas as much as our own
Find out more on roche.com/partnering

Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the “R&D dating for Animal Health and Innovation”, which strives to initiate high-level exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups).

By enabling face-to-face encounters, the event enhances the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.

Animal health-related roundtable discussions

Innovation and One Health: How can monoclonal antibodies offer new perspectives in veterinary medicines
Tuesday, November 9th | 2.30 - 3.00 pm | Madrid 1 room

Funding innovation and start-ups development in animal health
Tuesday, November 9th | 3.15 - 4.30 pm | Madrid 1 room

Organised by:

SIMV

6 programs in 5 indications
HOSTED EVENTS

Kick-off LEAP-BIO

Wednesday, November 30th | 9.00 – 11.00 am

Madrid 2 room

LEAP-BIO Opening Conference will be the opportunity to introduce the participants to the early-stage IP licensing intermediary service for biopharma SMEs and large companies that will be developed and offered, and how to benefit for it. The Conference will be followed by a discussion around the challenges of IP Licensing of early-stage assets in biopharma and intermediary services existing in Europe and beyond.

LEAP-BIO is a COSME project aiming to address a lack of intermediary services towards IP licensing and exploitation in key-target European regions/countries, such as Portugal, Spain, France, Italy and the Wallonian region (Belgium).

The main goal of the project is to leverage the extensive expertise and networks of the consortium to develop an early-stage focused IP licensing intermediary service for biopharma SMEs and start-up companies in the target regions - mainly Portugal, France, and Italy but also Spain and the Wallonian region in Belgium. LEAP-BIO aims at bridging the gap between southern, central, and northern European regions in licensing and partnering associated with early-stage assets, driving the growth of the small and medium biopharma companies in such regions and contributing to a more competitive European biopharma industry at a global level.

LEAP-BIO has 4 main priority axes:
- tool mapping and analysis,
- identification of the licensing interest in pharma & biotech companies,
- identification of early assets for licensing in start-ups and SMEs,
- connecting and matching pharma & biotech companies, start-ups, and SMEs.

Partners:

Capital Grand Est manages over €190M to invest in growing SMEs and in promising young Start-Ups located in the eastern part of France
The following companies exhibit at BioFIT, visit their stand!

**ACTEMIS - STAND G7-F8/3**
www.actemis.com
Actemis has been assisting Health start-ups (Biotech, MedTech) for several years in their search for funding for their Research, Development and Innovation activities and also on tax measures (CIR, CIL, J EI). The Actemis Health Unit will support you in all your projects thanks to the implementation of specific monitoring tools for Health companies as well as regular monitoring of calls for projects in the Health sector.

**ALSOLOGPHARMA - STAND D3**
www.alsalogpharma.com
Alsologpharma offers you an innovative service for your research and development activities. Our mission is to route your ultra-sensitive flows in accordance with your requirements, offering a guarantee of confidentiality, security, (real-time direct traceability) and processing speed. Our tailored solutions will offer you all the required support to provide you with the quality and technological maturity and help you focus on your core business: fundamental research.

**ABCCAM PLC - STAND F1**
www.abcam.com
Abcam is a global life science company enabling scientific breakthroughs by serving life scientists to achieve their mission, faster. We partner with global life science and clinical communities to deliver next-generation tools and solutions to help accelerate research and lead to new discoveries that positively impact society.

**ACROBIOSYSTEMS - STAND E5**
www.acrobiosystems.com
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the Life Sciences by providing products and services innovation. The company evolved in the pre-clinical phases, but also clinical, constitute the force of our sector; dynamic and highly qualified actors, constituting a diversified fabric of scientific providers essential to the development of industries in the Life Science.

**AND BIOPHARMA BV - STAND A5**
www.andbiopharma.eu
AND BioPharma BV uses patented technology to produce self inhibiting nucleotides that manage pathogen populations. Simply said: any organism ingesting, up taking or even in touch with too much selfDNA will stop growing, wither and die. We focus on topical livestock conditions in the tropics and in Europe.

**ACTOME - STAND A3**
www.actome.de
Actome’s Protein Interaction Coupling (PICO) technology supports life science research and development by enabling the quantification of proteins and protein interactions in biological samples with unprecedented ultra-high sensitivity and flexibility. The PICO technology combines the advantages of immunoassays and digital PCR by translating protein status into DNA barcodes. Our kits provide a simple and robust sample-to-result workflow.

**ANS BIOTECH - STAND F11-E12/10**
www.ans-biotech.com
ANS Biotech is a preclinical CRO exclusively dedicated to the in vivo pharmacology of Pain/Well-being. Our mission is to help our Clients to evaluate the efficacy of their candidates in our preclinical models of pain. Since 2006, we have accompanied more than 150 clients around the globe to build step by step their preclinical dossier. As an extension of your scientific team wherever you are located around the world, we help you to optimise and accelerate the development of your drug candidat.

**ARXUM - STAND A9**
www.arxum.com
ARXUM is a European software company based in Germany and specialised in industrial automation for the Pharma market. Since 2018, ARXUM has been a pioneer in cutting-edge technologies (blockchain & assisted reality) that are truly beneficial in biotech labs and pharmaceutical supply chain management. Thanks to a team of tech experts and the supports of the European Commission and the Polepharma, ARXUM offers state-of-the-art solutions to improve the biotech processes and data integrity.

**AFSSI - STAND F11-E12**
www.afssi.fr
The AFSSI, the French Association of Service and Innovation Companies for the Life Sciences has the desire to unite French companies of services and technological innovation in the strategic field of Life Sciences. These innovative companies evolve in the pre-clinical phases, but also clinical, constitute the force of our sector; dynamic and highly qualified actors, constituting a diversified fabric of scientific providers essential to the development of industries in the Life Science.

**ASKLESOFIT - STAND G7-F8/2**
www.asklesoft.com
Asklesoft digitalises your Qualifications & Validations from the URS to the PQ according to the requirements of the FDA 21 CFR Part 11 and the EMA Annex 11. Our cloud based solution is a powerful tool saving time, reducing your costs and giving you tools to drive your team more efficiently. Ask us for a free demo and change the way you process your FAT, SAT, IQ, OQ, PQ.
EXHIBITORS

ATLANTIC BONE SCREEN - STAND F11-E12/9
www.atlantic-bone-screen.com
Atlantic Bone Screen is a French CRO specialised in high-quality preclinical evaluation services. We have a strong know-how in the field of bone and joint diseases and in oncology. We provide in vitro tests, animal models and other technical services for imaging, histology and histopathology. We support our Customer to identify and characterise the therapeutic potential of drug candidates, nutraceuticals and biomaterials through tailor-made preclinical studies.

BIOVALLEY FRANCE - STAND B6
www.biovalley-france.com
Based in Grand Est Region, the Cluster BioValley France brings to the health sector its unique expertise and personalised support program around 4 fields of expertise: - drugs and innovative therapies: genetic and cellular therapies, bioproduction, clinical assessment tools... - medical technologies: robotics and image guided surgery, implantable medical devices... - e-health: simulation and decision support tools, patient follow-up... - diagnosis: biomarker, imaging, fast diagnosis...

BACHEM - STAND G11
www.bachem.com
Bachem is a leading, innovation-driven company specialising in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

BIPER THERAPEUTICS - STAND B6/5
www.biper-tx.com
BIPER TX is a biotech start-up developing first-in-class drug candidates against cancers with high unmet medical needs. Our first drug candidate, BPR001 is at 15 months from the clinic and has been developed to treat gastro-intestinal cancers in oral administration. Our first portfolio of patented small molecules target specifically BIP a key controller of the ER Stress, a pro-survival and resistance pathway, leading to tumour growth inhibition in a broad range of cancer indications.

CER GROUPE - STAND F7
www.cerglassgroup.be
CER Groupe is a CRO supporting human and veterinary health by providing research services to companies active in the biotech, pharma, food and agrotech fields. Our activities focus on non-clinical development, biomanufacturing and food testing services, supported by strong analytical platforms and expertises. Our teams are committed to offer flexible and integrated solutions, from discovery to toxicity evaluation and routine services, at the highest quality standards (ISO9001, ISO17025 and GLP).

CILCARE - STAND B11
www.cilcare.com
CILcare is the world’s leading R&D services company specialised in ear disorders. Based in Copenhagen, CILcare supports pharma, medtech, animal health and nutraceutical industries to assess efficacy and safety of drugs, cell & gene therapies, and medical devices, on hearing loss, tinnitus, otitis, and ototoxicity. CILcare’s mission is to make hearing a priority & give hope to the 1 billion people worldwide waiting for effective solutions.

CYNBIOSE - STAND F11-E12/5
www.cynbiose.com
Cynbiose is a non-clinical CRO specialised in non-human primate (NHP) models for biomedical research. We perform preclinical services ranging from exploratory DMPK, early safety and immunogenicity studies for NCEs, immunotherapies, gene therapies and vaccines. We also propose PoC studies in several therapeutic areas such as infectious and respiratory (BSL-2 to 3), CNS, immunology. Our France-based facility is AAALAC accredited and studies performed in a GLP-like environment.

CARBOGEN AMCIS - STAND E7
www.carbogen-amcis.com
CARBOGEN AMCIS leverages world-class chemistry skills to provide drug development and commercialisation services to pharmaceutical and biopharmaceutical companies. Our cGMP-compliant infrastructure includes dedicated Highly Potent facilities and a clean room for Antibody Drug Conjugates. We also offer high-quality Cholesterol and Vitamin D analogs. Learn more at www.carbogen-amcis.com.

CILOA SAS - STAND G9
www.ciloa.fr
Bio-engineered Exosomes to tackle diabetes, inflammation, infectious diseases and more. Ciloa is the most experienced exosome-based R&D power house dedicated to the development of preventive and therapeutic innovative solutions using a patented technology to bio-engineer exosomes. Its technology provides solutions to the major challenges in the development of exosome-based bio-therapeutics which are: targeting specificity, cargo loading, stability, and production of large amounts of pure exosome.

CLUBSTER NHL - STAND G7-F8
www.clubster-nhl.com
Clubster NHL – Nutrition, Health, Longevity – is a French competitiveness cluster federating 350 members in the Nutrition, biotechnology, and health sectors. We foster collaboration between academia, private companies (start-ups, SMEs and large companies), clinicians and final users. Our aim is to help our members to design, develop and finance their innovative products and processes.

BICRO BIOCENTRE - INCUBATION CENTRE FOR BIOSCIENCES - STAND E3
www.biocentre.hr
BIOCentre, Ltd. is biotech incubator and scientific research institution in Croatia. BIOCentre provides ofices and laboratories, conduct training and consultancy start-ups established biotech companies, connects companies, universities and institutes. Central Laboratory’s specialised units Microbiology, Cell biology, Downstream processing, Proteomics and Bioanalytical chemistry are specialised to design the process optimisation from biomass production up to a final biological product.

CILIOA SAS - STAND G9
www.ciloa.fr
Bio-engineered Exosomes to tackle diabetes, inflammation, infectious diseases and more. Ciloa is the most experienced exosome-based R&D power house dedicated to the development of preventive and therapeutic innovative solutions using a patented technology to bio-engineer exosomes. Its technology provides solutions to the major challenges in the development of exosome-based bio-therapeutics which are: targeting specificity, cargo loading, stability, and production of large amounts of pure exosome.

CILCARE - STAND B11
www.cilcare.com
CILcare is the world’s leading R&D services company specialised in ear disorders. Based in Copenhagen, CILcare supports pharma, medtech, animal health and nutraceutical industries to assess efficacy and safety of drugs, cell & gene therapies, and medical devices, on hearing loss, tinnitus, otitis, and ototoxicity. CILcare’s mission is to make hearing a priority & give hope to the 1 billion people worldwide waiting for effective solutions.

CLUBSTER NHL - STAND G7-F8
www.clubster-nhl.com
Clubster NHL – Nutrition, Health, Longevity – is a French competitiveness cluster federating 350 members in the Nutrition, biotechnology, and health sectors. We foster collaboration between academia, private companies (start-ups, SMEs and large companies), clinicians and final users. Our aim is to help our members to design, develop and finance their innovative products and processes.

CYNBIOSE - STAND F11-E12/5
www.cynbiose.com
Cynbiose is a non-clinical CRO specialised in non-human primate (NHP) models for biomedical research. We perform preclinical services ranging from exploratory DMPK, early safety and immunogenicity studies for NCEs, immunotherapies, gene therapies and vaccines. We also propose PoC studies in several therapeutic areas such as infectious and respiratory (BSL-2 to 3), CNS, immunology. Our France-based facility is AAALAC accredited and studies performed in a GLP-like environment.

CARBOGEN AMCIS - STAND E7
www.carbogen-amcis.com
CARBOGEN AMCIS leverages world-class chemistry skills to provide drug development and commercialisation services to pharmaceutical and biopharmaceutical companies. Our cGMP-compliant infrastructure includes dedicated Highly Potent facilities and a clean room for Antibody Drug Conjugates. We also offer high-quality Cholesterol and Vitamin D analogs. Learn more at www.carbogen-amcis.com.

BICRO BIOCENTRE - INCUBATION CENTRE FOR BIOSCIENCES - STAND E3
www.biocentre.hr
BIOCentre, Ltd. is biotech incubator and scientific research institution in Croatia. BIOCentre provides ofices and laboratories, conduct training and consultancy start-ups established biotech companies, connects companies, universities and institutes. Central Laboratory’s specialised units Microbiology, Cell biology, Downstream processing, Proteomics and Bioanalytical chemistry are specialised to design the process optimisation from biomass production up to a final biological product.

CILCARE - STAND B11
www.cilcare.com
CILcare is the world’s leading R&D services company specialised in ear disorders. Based in Copenhagen, CILcare supports pharma, medtech, animal health and nutraceutical industries to assess efficacy and safety of drugs, cell & gene therapies, and medical devices, on hearing loss, tinnitus, otitis, and ototoxicity. CILcare’s mission is to make hearing a priority & give hope to the 1 billion people worldwide waiting for effective solutions.

CYNBIOSE - STAND F11-E12/5
www.cynbiose.com
Cynbiose is a non-clinical CRO specialised in non-human primate (NHP) models for biomedical research. We perform preclinical services ranging from exploratory DMPK, early safety and immunogenicity studies for NCEs, immunotherapies, gene therapies and vaccines. We also propose PoC studies in several therapeutic areas such as infectious and respiratory (BSL-2 to 3), CNS, immunology. Our France-based facility is AAALAC accredited and studies performed in a GLP-like environment.

CILCARE - STAND B11
www.cilcare.com
CILcare is the world’s leading R&D services company specialised in ear disorders. Based in Copenhagen, CILcare supports pharma, medtech, animal health and nutraceutical industries to assess efficacy and safety of drugs, cell & gene therapies, and medical devices, on hearing loss, tinnitus, otitis, and ototoxicity. CILcare’s mission is to make hearing a priority & give hope to the 1 billion people worldwide waiting for effective solutions.

CYNBIOSE - STAND F11-E12/5
www.cynbiose.com
Cynbiose is a non-clinical CRO specialised in non-human primate (NHP) models for biomedical research. We perform preclinical services ranging from exploratory DMPK, early safety and immunogenicity studies for NCEs, immunotherapies, gene therapies and vaccines. We also propose PoC studies in several therapeutic areas such as infectious and respiratory (BSL-2 to 3), CNS, immunology. Our France-based facility is AAALAC accredited and studies performed in a GLP-like environment.
Domain Therapeutics is a clinical-stage biotech delivering immunotherapies targeting GPCR-mediated immunosuppression. Our high-value proprietary programs consist of first-in-class and best-in-class strategically positioned assets regarding tumor subtypes and patient subpopulations for optimal outcome.

Deeptope offers a deeptech methodology for therapeutic protein development. It combines high throughput in vitro mutagenesis, Yeast Display, FACS and NGS to characterise protein interactions and perform multiparametric lead optimisation.

Eurosanté is a development agency dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, startups and companies with their development projects. To do so, Eurosanté provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurosante Bio-business Park, which already hosts 10 hospitals, 4 universities, 8 specialised schools and more than 200 companies. It benefits from an exceptional location at the heart of Europe.

Eurosanté CDMO provides integrated, end-to-end development and manufacturing services for Drug Substance/API and Drug Product of small molecules and biologics. Our services: Formulation Development, Non-GMP & GMP Manufacturing (Sterile & Non-sterile), Clinical Packaging and Logistics including for highly potent compounds, poorly soluble drugs, lyophilisation processes and specific therapeutic areas (immunotherapies, orphan drugs, pediatric dosage forms, ...).

Dom Therapeutics is a clinical-stage biotech delivering immunotherapies targeting GPCR-mediated immunosuppression. Our high-value proprietary programs consist of first-in-class and best-in-class strategically positioned assets regarding tumor subtypes and patient subpopulations for optimal outcome.

Drugablis is an established CRO specialised in pharmaceutical druggability of R&D compounds, including cytotoxic drugs. Our expertise includes API Solid Form Optimisation (salts, polymorphs, cocrystals) & Early Formulation, ranging from animal formulation (efficacy, PK, Tox) to early clinical formulation feasibility assessment (oral low soluble, injectable, ocular, dermal, vaginal ...). Our new facilities and recent hirings and new equipments allow us increasing our capacities for new projects.

Enterosys is specialised in the preclinical evaluation of compounds of interest on the digestive sphere, the enteric nervous system and the communication between the gut and peripheral organs. Thanks to innovative state-of-the-art techniques based on the analysis of physiological parameters in real time, our expertise allows us to develop proofs of concept and to study precisely the mechanisms of action of molecules of therapeutic interest (i.e. drug candidates, dietary supplements, ...).

Eurosanté CDMO is part of the Eurosanté Group and an internationally leading provider of Sanger DNA sequencing services, NGS services, genotyping services, DNA & RNA synthesis and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The company's strength is its extensive customer base and high-quality services in industrial and academic research projects. The company is dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, startups and companies with their development projects. To do so, Eurosanté provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurosante Bio-business Park, which already hosts 10 hospitals, 4 universities, 8 specialised schools and more than 200 companies. It benefits from an exceptional location at the heart of Europe.

Eurosanté is a development agency dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, startups and companies with their development projects. To do so, Eurosanté provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurosante Bio-business Park, which already hosts 10 hospitals, 4 universities, 8 specialised schools and more than 200 companies. It benefits from an exceptional location at the heart of Europe.

Eurosanté is a development agency dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, startups and companies with their development projects. To do so, Eurosanté provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurosante Bio-business Park, which already hosts 10 hospitals, 4 universities, 8 specialised schools and more than 200 companies. It benefits from an exceptional location at the heart of Europe.

Evoly Consulting is an innovation funding management consulting company created in 2012. Based in Lyon, we combine the expertise of our multidisciplinary team to offer strategic and operational consulting services across Europe. Whether you are a start-up, an SME or a multinational, we use our expertise to identify and activate the funding mechanisms appropriate to your R&D and innovation projects.

FastCompChem aims at improving drug discovery through accurate quantum chemical methods. With very high rates of attrition due to safety concerns, having early accurate predictions of possible toxic effects will dramatically improve the process of drug discovery. Ultimately, only compounds with good safety profiles should proceed to clinical trials. FastCompChem is developing quantum computational toxicology tools for early stage drug discovery.

Eurosanté CDMO provides integrated, end-to-end development and manufacturing services for Drug Substance/API and Drug Product of small molecules and biologics. Our services: Formulation Development, Non-GMP & GMP Manufacturing (Sterile & Non-sterile), Clinical Packaging and Logistics including for highly potent compounds, poorly soluble drugs, lyophilisation processes and specific therapeutic areas (immunotherapies, orphan drugs, pediatric dosage forms, ...).

Eurosanté CDMO provides integrated, end-to-end development and manufacturing services for Drug Substance/API and Drug Product of small molecules and biologics. Our services: Formulation Development, Non-GMP & GMP Manufacturing (Sterile & Non-sterile), Clinical Packaging and Logistics including for highly potent compounds, poorly soluble drugs, lyophilisation processes and specific therapeutic areas (immunotherapies, orphan drugs, pediatric dosage forms, ...).

Eurosanté is a development agency dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, startups and companies with their development projects. To do so, Eurosanté provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurosante Bio-business Park, which already hosts 10 hospitals, 4 universities, 8 specialised schools and more than 200 companies. It benefits from an exceptional location at the heart of Europe.

Eurosanté is a development agency dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, startups and companies with their development projects. To do so, Eurosanté provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurosante Bio-business Park, which already hosts 10 hospitals, 4 universities, 8 specialised schools and more than 200 companies. It benefits from an exceptional location at the heart of Europe.
EXHIBITORS

FIRALIS MOLECULAR PRECISION
STAND F6
www.firalis.com

Firalis is a French biotech company based in France, at the border with Switzerland and Germany. The company was created 15 years ago and specializes in biomarker discovery and personalized medicine services. We support international drug research and development with academia, biotechs and pharmaceutical labs by providing sample analysis services in Neurology, Oncology and Immunology. Thanks to our cutting-edge analytical tools and expert team, we bring a complete multi-omics approach.

GRAND EST REGION - STAND B6
www.grandest.fr

Located in the heart of Europe, Grand Est is a very attractive territory and a leading player in the health industry. Our regional innovation strategy (S3 2021-27) has clearly highlighted the high growth potential of health market in three sectors: medical devices, biotechnology and digital health tools. Our ambition is now to accelerate economic transitions and create a unique environment to attract new players and promote excellence in research and innovation initiatives.

INNOSER / CONNECTED-PATHOLOGY
STAND F5
www.innoselieraboratories.com

As an innovative and dynamic contract research organization (CRO), InnoSer supports the preclinical pipeline from its facilities in Belgium and the Netherlands. Founded in 2012, our in-depth expertise allows us to provide customized and streamlined early drug development options with well-characterized and near-patient research models.

MARSHALL BIORESOURCES
STAND F11-E12/6
www.marshallbio.com

Our mission is to be the premier source of animal models and related services for the preclinical research and development of human medicines, vaccines, medical devices, and other therapies, as well as for the clinical research and development of companion animal pharmaceuticals. For over 80 years our animals have contributed to the development of life saving therapies and treatments for humans and animals alike. We hold ourselves to the highest standards of health and quality, and AAALAC acc.

FLEMING ASSOCIES - STAND G7-F8/A
Fleming Associés

Fleming Associés, Insurance Partner Facilitator of Businesses impacting Health and Healing.

We are specialise in insurance for clinical trial, public liability of biotech companies, cyber risk, P&C insurance (laboratory, offices...). We make true commitments in terms of quick response and sending times (responsiveness), follow-up points for clients care, defense in case of disaster.

HC NEXT - STAND G7-F8/1
www.hc-next.com

HC NEXT is specialized in project management and vendor management for drug development. We support pharma and biotech to:
- Structure the project, with all its components, to secure and accelerate the passage of key milestones
- Optimise the generation and organisation of valid and relevant data
- Select & coordinate the vendors (Clinical, CMC, Regulatory, Quality Assurance...)
- Catch up on a drifting project

Eurasanté preferred partner, we also support incubated companies in early-stages.

LIFESPIN GMBH - STAND A2
www.lifespinn.health

Lifespin is building a smart health diagnostic platform that combines biology and data science to enable digital metabolic profiles, with currently more than 30,000 individuals, enables the analysis of more than one billion metabolic relationships.

MEDITOX S.R.O. - STAND E4
www.meditox.eu

MediTox is a GLP-certified CRO having experience in variety of compounds and therapeutic areas, with an experts and associates teams capable to conduct a number of experiments in full compliance with GLP standards and with another international guidelines (EMA/ICH, VICH, OECD, US FDA, ISO 90093), providing core range of nonclinical studies supporting phases I - III of clinical trials and/or registration of human & veterinary drugs, medical device, food/feed additives.

FRANCE BIOTECH - STAND B1
www.france-biotech.fr

France Biotech is an independent association that brings together the country’s leading innovative health companies. As a leader in health innovation and a privileged intermediary with public authorities in France and Europe, France Biotech’s mission is to support the development of this industry in France, by improving the tax, legal, regulatory and managerial environment in which these companies operate and by advocating for their recognition as a leading-edge industry.

ILONOV - STAND B6/8
www.ilonov-diabetes.com

Itonov is a preclinical stage biotech developing first-in-class biologics against chronic metabolic diseases, harvesting the potential of muscle secretome to regulate metabolism, a novel & unexplored approach. Our biotherapy specifically preserves & stimulates pancreatic beta cell function by restoring the integrity of the extracellular matrix of the islet niche. Discovered in human muscle post-exercise, our asset has already proven safety & efficacy in preclinical T1D & T2D models in vivo.

MABEXPERTS GROUP: RD-BIOTECH & SYNABS - STAND C10
www.mabexperts.com

RD-BIOTECH & SynAbs are part of MABEXPERTS, an European alliance of synergetic companies combining high expertise, technical skills and scientific know-how in Antibody Engineering: From DNA to Biotherapeutics.

SYNABS: Proprietary technologies and rat-LOU species, mAb development, high success rate in generating Ab against difficult targets.

RD-BIOTECH: Custom development and biomanufacturing of pDNA, mAb, recombinant protein and antibody (Fab, scFv...). From pilote to large scale.

MICROSynth - STAND E8
www.microsynth.com

Microsynth (founded in 1989) is a leading European company in nucleic acid synthesis & analysis. The main activities are divided into following three business areas:
1. DNA/RNA Synthesis
2. DNA/RNA Analysis and Sequencing
3. Contract Research/Outsourcing
MINAKEM SAS - STAND C4
www.minakem.com
As a leading European CDMO, Minakem offers services for the process development, scale-up, commercial GMP production and full life cycle management of small molecules APIs & HPAPIs. Our process optimisation and technical transfer approach is driven by Operational Excellence, with a focus on quality every step of the way. In successful long-term partnerships, we support pharmaceutical and biotechnological companies in the development and manufacture of innovative treatments.

NOVALIX - STAND B5
www.novalix.com
Drug discovery CRO from gene to optimised lead. With more than 200 researchers, screening, fragments, covalent fragments and DEL. Biophysics: mass spectrometry, SPR, NMR, MST, DSF, HDX. Structural Biology: protein X-ray crystallography and cryo-EM — including membrane proteins. Chemistry: custom synthesis, process research, medicinal chemistry. Award winning medicinal chemists for integrated projects.

PFIZER CENTREONE - STAND C2
www.pfizercentreone.com
Pfizer CentreOne® is a global CDMO within Pfizer and a leading supplier of specialty APIs. Our global manufacturing network includes more than 35 sites across six continents. Backed by Pfizer resources, we deliver technical expertise, global regulatory support and long-term supply. Working together with our customers, we combine our knowledge with open dialogue to solve challenges. For more information, visit www.pfizercentreone.com.

POLYPEPTIDE GROUP - STAND A8
www.polypeptide.com
PolyPeptide is a focused Contract Development & Manufacturing Organisation (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics.

MYDATA-TRUST - STAND B9
www.mydata-trust.com
MyData-TRUST is the leading company specialised in Data Protection & Privacy, exclusively dedicated to the Life Sciences Industry. Our objective is to help organisations to comply with worldwide data protection regulations including EU/UK GDPR, US HIPAA, Swiss FADP, Chinese PIPL and Brazilian LGPD. Our services cover: training & education, risk assessments, legal support, externalised Data Protection Officer and Data Protection Representative.

OXELTIS - STAND F11-E12/7
www.oxeltis.com
Oxeltis is a medchem services company with hit to lead optimisation services in various therapeutic fields. Oxeltis’ scientific team has a recognised expertise in specific areas of organic synthesis: heterocycles, macrocycles, nucleosides/nucleotides, phosphoramidites, modified sugars, oligo/poly saccharides, and PROTAC. Oxeltis has completed over 35 projects and several drug candidates delivered to its customers are in clinical development. Oxeltis works in EU, Japan and North America.

PHARMALEX - STAND F11-E12/8
www.pharmalex.com
PharmaLex is the leading provider of specialised services for the pharma, biotech and MedTech industries. We guide you from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-enabled solutions to support you through the entire product lifecycle delivering tailor-made solutions worldwide.

PROTEOGENIX - STAND B6/3
www.proteogenix.science
ProteoGenix is a leading life sciences organisation which has been providing services in molecular biology, protein engineering and immunology since 2003. ProteoGenix is a French CRO with more than 19 years of experience in the following areas: - Antibody engineering (Humanization, Bi-specific, ADC, stable cell line development) - Monoclonal and polyclonal antibody development (Phage display, single B cell sorting, hybridoma) - Recombinant protein/antibody production (5 different systems)

POLY-DTECH - STAND D6
www.poly-dtech.com
Poly-Dtech: A company specialised in the R&D of fluorescent nanomolecules in the field of healthcare and life sciences. Our patented cutting-edge technology consists of ultra-fluorescent nanoparticles with unique features, offering an unrivaled performance that exceeds the current technical limits and allows the detection of various biomarkers far beyond what is possible nowadays, with user-friendly protocols and applicable to various molecular and cellular biology techniques.

RÉSEAU SATT - STAND C7-B12
www.satt.fr
The SATT Network brings together 13 Technology Transfer Acceleration Companies in France. Committed to economic dynamism thanks to the scientific innovations resulting from public research, SATTs provide companies with high-potential technological solutions to improve their competitiveness. With more than 650 startups created, the SATTs are the leading local players in the French government’s DeepTech Plan, operated by Bpifrance. They are supported by a public action to more than 150,000 researchers and offer privileged access to innovations from public laboratories. With their national network, they are the strategic partners of companies seeking growth through innovation.
RONDOL - STAND E10
www.rondol.com

RONDOL aims to adapt extrusion to the micro scale and to pharmaceutical standards, contributing to more efficient medicines and medical devices, with less side effects and toxicity, greener and cheaper. RONDOL was nominated at the Galien Awards, signed a global technology partnership with SEQUENS and a research agreement against child malaria with BASF and QUB. Rondol provides horizontal and vertical extruders that meet the criteria of regulatory agencies.

SCINOPSIS - STAND A6
www.scinopsis.com

Scinopsis is an experienced medical writing consultancy providing high-quality documents for the pharmaceutical, biotechnology and medical device industries. We offer a comprehensive medical writing service to cover your regulatory/clinical and medical communications needs, from early clinical development up to registration and post-approval, across all therapeutic areas. Scinopsis is well known for its flexible and friendly attitude and we will always endeavour to find the right solution.

ROOWIN - STAND F9
www.roowin.com

Roowin is a privately owned Contract Research Organisation (CRO) headquartered at Riom, Auvergne, France. Its core business being in high value added fine chemistry, Roowin offers services in the following areas:
- GMP synthesis
- Process development
- Analytical methods
and more

We are proud to be able to accompany our customers from early drug discovery over process development to medium-scale GMP production, supporting our operations by strong analytical chemistry capabilities.

SELVITA - STAND E9
selvita.com

Selvita is a preclinical CRO providing multidisciplinary support in resolving challenges of research within the area of drug discovery and drug development. Selvita was established in 2007 and currently employs over 100 professionals, of which over 40% hold a PhD degree. The Company research sites are located in Krakow (HQ) and Poznan, Poland, as well as Zagreb, Croatia. The company offers drug discovery support at every stage of the early discovery phase up to the preclinical development.

SPARTHA MEDICAL - STAND B6/6
www.sparthamedical.eu

SPARTHA Medical develops multifunctional coatings for medical devices and for daily use. Our patented coatings have antiviral, antimicrobial, and anti-inflammatory effects while avoiding bacterial resistance. We develop customised, implant-specific coatings that reduce implant-related complications. The coatings are intended for almost all complex surfaces of a wide range of medical devices (implants, dressings, surgical materials, ...) as well as non-medical materials.

SERVIER - STAND C6
www.servier.com

Servier is a global independent pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.78€ in 2021, Servier employs 21,800 people worldwide. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. Servier growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neurosciences and immunoinflammatory diseases.

STEMINOV - STAND B6/4
StemInov

StemInov is a clinical stage spin-off from CHRU of Nancy and University of Lorraine that develops an off-the-shelf and allogenic cell therapy treatment in the field of inflammatory pathologies with a focus on critical care. More than a new product, our proprietary Stem cells from the Wharton jelly of umbilical cord, called WhartSep, is a new concept of immunomodulation and adaptive medicine firstly indicated and patented for the treatment of septic shock and Acute Respiratory Syndrome Disease.

SYNGENE - STAND B4
www.syngeneintl.com

Syngene is an integrated CRO/CDMO serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. We offer end-to-end development and manufacturing services to advance clinical candidates from preclinical to NDA filing with ease. Our high-end capabilities for small molecules and biologics extend across drug substance, drug product, analytical development, ICH stability studies, commercial manufacturing, and clinical development.
EXHIBITORS

TEMESIS THERAPEUTICS - STAND B6/1
www.temisis.com

Founded in 2017, Temesis is a biotechnology company focused on the discovery and development of novel small molecule compounds to treat inflammatory diseases with high unmet needs. TEM1657, our lead program has showed great efficacy in preclinical studies, both orally and topically, relieving psoriasis symptoms without the side effects associated with existing treatments. TEM1657 unique efficacy and safety profile is explained by its first-in-class MoA, currently under investigation.

UNIVERSITY HOSPITAL HRADEC KRÁLOVÉ - STAND E6
www.fnhk.cz

Founded in 1887, as one of the first university hospital worthy of the name, to soon become one of the largest medical facility not only in Eastern Bohemia, but also throughout the Czechia. The most complex surgical procedures are performed and modern diagnostic and treatment technologies are used. This makes our hospital comparable to similar hospitals in Europe. In research, the UH HK aims to get the position of a leader in the fields of epigenetics, microbiomics and the emerging Next-Gen Sequencing space. With international facilities and a global distribution network, Zymo Research enables researchers in academia and the biomedical field to make cutting-edge discoveries all over the world and provides some of the most technologically advanced products in the industry.

WAINVAM-E - STAND B3
www.wainvam-e.com

WAINVAM-E is a young company developing quantum sensors based on the special optic and quantic properties of diamonds with Nitrogen Vacancy centers. Our instruments are highly sensitive, accurate and stable. They represent a new generation of diagnostic and control tools, with a wide range of applications in many fields, from non-destructive testing for the energy, aeronautics fields, to the detection and diagnostic testing for the pharmaceutical and medical fields.

X’PROCHEM - STAND E2
www.xprochem.com

X’PROCHEM is a biotech company specialised in chemical synthesis of proteins for therapeutic and diagnostic use. We are able to design and produce complex and highly customised proteins thanks to our robotic technology. We can help you to produce proteins that are:
- Difficult to produce or to purify
- Need unnatural amino acids
- More efficient and reliable
- Proteins composed of up to 400 amino acids
- Contain a precise modification in the protein sequence

Our proteins are guaranteed high purit, no endotoxins or biological contaminants and no isoforms.

XPRESS BIOLOGICS - STAND F4
www.xpress-biologics.com

Xpress Biologics is a dynamic and customer-oriented Contract Development and Manufacturing Organisation (CDMO) specialised in the development of manufacturing processes based on microbial expression systems (E. coli and P. pastoris) and the production of Biologics (recombinant proteins, antibody fragments and plasmid DNA) for the therapeutic, vaccine and diagnostic markets.

YESMYPATENT - STAND D4
www.yesmypatent.com

YesMyPatent is the digital service of IP firm Touroude & Associates, aiming at democratising patent filing. Innovation protection shall be accessible to all, in terms of costs, expertise quality and access to resources. We provide patent services worldwide through trusted foreign associates in each country. At YesMyPatent by T&A, we give guidance to individual inventors, start-up, large entities or public research groups who request a cost-efficient management of their IP.

XPRIS HOSPITAL HRADEC KRÁLOVÉ - STAND E6
www.xpris.com

XPRIS is a hospital located in the city of Hradec Králové, Czech Republic. Founded in 2010, XPRIS is a modern medical facility providing comprehensive healthcare services to the local population and beyond. The hospital offers a wide range of medical specialties, including surgery, internal medicine, pediatrics, and more. XPRIS is equipped with state-of-the-art facilities and technology, ensuring that patients receive the highest quality care. The hospital is committed to advancing medical knowledge and research, contributing to the development of innovative treatments and diagnostic procedures. XPRIS also places a strong emphasis on patient care and satisfaction, striving to create a positive and comfortable environment for all who seek treatment. Whether you need routine medical care or are facing a complex health issue, XPRIS is here to support you on your path to recovery.

WAINVAM - STAND B3
www.wainvam.com

WAINVAM is a company that develops quantum sensors based on the special properties of diamonds with Nitrogen Vacancy centers. These sensors are highly sensitive, accurate, and stable and are used in various fields such as energy, aeronautics, and pharmaceuticals.

X’PROCHEM - STAND E2
www.xprochem.com

X’PROCHEM is a biotech company specialized in chemical synthesis of proteins for therapeutic and diagnostic use. They offer custom protein production services, providing complex and highly定制 proteins.

XPRESS BIOLOGICS - STAND F4
www.xpress-biologics.com

Xpress Biologics is a CDMO specialized in the development of manufacturing processes for recombinant proteins. They offer services such as antibody fragments, plasmid DNA production, and diagnostic testing.

YESMYPATENT - STAND D4
www.yesmypatent.com

YesMyPatent provides patent services worldwide through trusted foreign associates, offering cost-efficient and high-quality innovation protection to individual inventors, start-ups, entities, and research groups.

XPRIS HOSPITAL HRADEC KRÁLOVÉ - STAND E6
www.xpris.com

XPRIS is an advanced hospital that offers comprehensive medical services to the local population and beyond. Founded in 2010, the hospital is equipped with modern facilities and technology, ensuring high-quality care for patients.

XPRIS HOSPITAL HRADEC KRÁLOVÉ - STAND E6
www.xpris.com

XPRIS is a hospital located in Hradec Králové, Czech Republic. The hospital offers a wide range of medical specialties, ensuring that patients receive the best care possible. It is committed to promoting health and wellness while supporting patients through the healthcare journey.

ZYMOSAN - STAND C5
www.zymoresearch.de

Zymo Research is a globally established biotechnology company and industry leader in the fields of epigenetics, microbiomics, and emerging Next-Gen Sequencing space. With international facilities and a global distribution network, Zymo Research enables researchers in academia and the biomedical field to make cutting-edge discoveries all over the world and provides some of the most technologically advanced products in the industry.

ZOETIS - STAND C5
www.zoetis.com

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, we continue to stand by those raising and caring for animals worldwide - from livestock farmers to veterinarians and pet owners. A Fortune 500 company, we generated revenue of $7.8 billion in 2021 with ~12,100 employees. For more, visit www.zoetis.com.

YESMYPATENT - STAND D4
www.yesmypatent.com

YesMyPatent is the digital service of IP firm Touroude & Associates, aiming at democratising patent filing. Innovation protection shall be accessible to all, in terms of costs, expertise quality and access to resources. We provide patent services worldwide through trusted foreign associates in each country. At YesMyPatent by T&A, we give guidance to individual inventors, start-up, large entities or public research groups who request a cost-efficient management of their IP.

WAINVAM - STAND B3
www.wainvam.com

WAINVAM is a young company developing quantum sensors based on the special properties of diamonds with Nitrogen Vacancy centers. These sensors are highly sensitive, accurate, and stable and are used in various fields such as energy, aeronautics, and pharmaceuticals.

X’PROCHEM - STAND E2
www.xprochem.com

X’PROCHEM is a biotech company specialized in chemical synthesis of proteins for therapeutic and diagnostic use. They offer custom protein production services, providing complex and highly customized proteins.

XPRESS BIOLOGICS - STAND F4
www.xpress-biologics.com

Xpress Biologics is a dynamic and customer-oriented Contract Development and Manufacturing Organisation (CDMO) specialized in the development of manufacturing processes based on microbial expression systems (E. coli and P. pastoris) and the production of Biologics (recombinant proteins, antibody fragments and plasmid DNA) for the therapeutic, vaccine and diagnostic markets.

UNIVERSITY HOSPITAL HRADEC KRÁLOVÉ - STAND E6
www.fnhk.cz

Founded in 1887, as one of the first university hospital worthy of the name, to soon become one of the largest medical facility not only in Eastern Bohemia, but also throughout the Czechia. The most complex surgical procedures are performed and modern diagnostic and treatment technologies are used. This makes our hospital comparable to similar hospitals in Europe. In research, the UH HK aims to get the position of a research facility capable of participation in European research activities.

ZYMOSAN - STAND C5
www.zymoresearch.de

Zymo Research is a globally established biotechnology company and industry leader in the fields of epigenetics, microbiomics, and emerging Next-Gen Sequencing space. With international facilities and a global distribution network, Zymo Research enables researchers in academia and the biomedical field to make cutting-edge discoveries all over the world and provides some of the most technologically advanced products in the industry.

XPRIS HOSPITAL HRADEC KRÁLOVÉ - STAND E6
www.xpris.com

XPRIS is a hospital located in Hradec Králové, Czech Republic. Founded in 2010, XPRIS is a modern medical facility providing comprehensive healthcare services to the local population and beyond. The hospital offers a wide range of medical specialties, including surgery, internal medicine, pediatrics, and more. XPRIS is equipped with state-of-the-art facilities and technology, ensuring that patients receive the highest quality care. The hospital is committed to advancing medical knowledge and research, contributing to the development of innovative treatments and diagnostic procedures. XPRIS also places a strong emphasis on patient care and satisfaction, striving to create a positive and comfortable environment for all who seek treatment. Whether you need routine medical care or are facing a complex health issue, XPRIS is here to support you on your path to recovery.

XPRIS HOSPITAL HRADEC KRÁLOVÉ - STAND E6
www.xpris.com

XPRIS is a hospital located in Hradec Králové, Czech Republic. Founded in 2010, XPRIS is a modern medical facility providing comprehensive healthcare services to the local population and beyond. The hospital offers a wide range of medical specialties, including surgery, internal medicine, pediatrics, and more. XPRIS is equipped with state-of-the-art facilities and technology, ensuring that patients receive the highest quality care. The hospital is committed to advancing medical knowledge and research, contributing to the development of innovative treatments and diagnostic procedures. XPRIS also places a strong emphasis on patient care and satisfaction, striving to create a positive and comfortable environment for all who seek treatment. Whether you need routine medical care or are facing a complex health issue, XPRIS is here to support you on your path to recovery.

XPRIS HOSPITAL HRADEC KRÁLOVÉ - STAND E6
www.xpris.com

XPRIS is a hospital located in Hradec Králové, Czech Republic. Founded in 2010, XPRIS is a modern medical facility providing comprehensive healthcare services to the local population and beyond. The hospital offers a wide range of medical specialties, including surgery, internal medicine, pediatrics, and more. XPRIS is equipped with state-of-the-art facilities and technology, ensuring that patients receive the highest quality care. The hospital is committed to advancing medical knowledge and research, contributing to the development of innovative treatments and diagnostic procedures. XPRIS also places a strong emphasis on patient care and satisfaction, striving to create a positive and comfortable environment for all who seek treatment. Whether you need routine medical care or are facing a complex health issue, XPRIS is here to support you on your path to recovery.
ONLINE MEETINGS
As an on-site delegate with access to the partnering platform, you can also schedule online meetings on December 7\textsuperscript{th} and 8\textsuperscript{th} to e-meet your future partners.

Please check your agenda for those 2 days on the digital platform biofit2022.vimeet.events. You may have meetings scheduled, please make sure you honour them. In case you already met a participant on November 29\textsuperscript{th} or 30\textsuperscript{th} in Strasbourg, do not forget to cancel your online meeting.

In addition, you can continue to send meeting requests and manage your meetings until December 7\textsuperscript{th} & 8\textsuperscript{th}.

How to access your virtual meetings?
5 minutes before a meeting, a START button will appear in the MY AGENDA tab on biofit2022.vimeet.events. By clicking on it, you will enter a virtual room. The meeting will start as soon as the person you are meeting is also logged in. You will then be able to share your screen.

LIVE CHAT
A live chat will be available in the NETWORKING tab on biofit2022.vimeet.events. Access the list of participants connected at the same time as you and chat by private message. It is possible to launch a 15-minute video call as soon as your message has been answered.

CONFERENCES AND PITCH SESSIONS ON-DEMAND
Recording of the on-site conference panels and video presentations of the 2022 BioFIT pitchers will be available on the platform in the PROGRAMME and PRESENTING COMPANIES tabs, respectively. This on-demand content will be available on the digital platform for a month.

BioFIT continues on December 7\textsuperscript{th} & 8\textsuperscript{th}!
SAVE THE DATE

Biofit FOSTERING INNOVATION & TRANSFER

The leading European partnering event for early-stage deals and investment rounds in the Life Sciences field

December 12th & 13th, 2023
MARSEILLE

12th EDITION

Organisers: [Logos]
Institutional partners: [Logos]
Sponsors: [Logos]